Loading…

Catatonia Secondary to Sudden Clozapine Withdrawal: A Case with Three Repeated Episodes and a Literature Review

A literature search identified 9 previously published cases that were considered as possible cases of catatonia secondary to sudden clozapine withdrawal. Two of these 9 cases did not provide enough information to make a diagnosis of catatonia according to the Diagnostic and Statistical Manual, 5th E...

Full description

Saved in:
Bibliographic Details
Published in:Case reports in psychiatry 2017-01, Vol.2017 (2017), p.1-11
Main Authors: Bilbily, John, de Leon, Jose, McCollum, Betsy
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4161-5f21535402edd91014fed39f8729115fd3b61a20b2f79185e244e856549b4b593
cites cdi_FETCH-LOGICAL-c4161-5f21535402edd91014fed39f8729115fd3b61a20b2f79185e244e856549b4b593
container_end_page 11
container_issue 2017
container_start_page 1
container_title Case reports in psychiatry
container_volume 2017
creator Bilbily, John
de Leon, Jose
McCollum, Betsy
description A literature search identified 9 previously published cases that were considered as possible cases of catatonia secondary to sudden clozapine withdrawal. Two of these 9 cases did not provide enough information to make a diagnosis of catatonia according to the Diagnostic and Statistical Manual, 5th Edition (DSM-5). The Liverpool Adverse Drug Reaction (ADR) Causality Scale was modified to assess ADRs secondary to drug withdrawal. From the 7 published cases which met DSM-5 catatonia criteria, using the modified scale, we established that 3 were definitive and 4 were probable cases of catatonia secondary to clozapine withdrawal. A new definitive case is described with three catatonic episodes which (1) occurred after sudden discontinuation of clozapine in the context of decades of follow-up, (2) had ≥3 of 12 DSM-5 catatonic symptoms and serum creatinine kinase elevation, and (3) required medical hospitalization and intravenous fluids. Clozapine may be a gamma-aminobutyric acid (GABA) receptor agonist; sudden clozapine withdrawal may explain a sudden decrease in GABA activity that may contribute to the development of catatonic symptoms in vulnerable patients. Based on the limited information from these cases, the pharmacological treatment for catatonia secondary to sudden clozapine withdrawal can include benzodiazepines and/or restarting clozapine.
doi_str_mv 10.1155/2017/2402731
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_8552c8010e4442ada71d92e4e95ec295</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A551495615</galeid><doaj_id>oai_doaj_org_article_8552c8010e4442ada71d92e4e95ec295</doaj_id><sourcerecordid>A551495615</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4161-5f21535402edd91014fed39f8729115fd3b61a20b2f79185e244e856549b4b593</originalsourceid><addsrcrecordid>eNqNkkFvEzEQhVcIRKvSG2dkiSOk9XjtXZsDUhSVUikSEi2CmzW7nk0cJevg3W0Ev75OE1IiccA-2Bp_8zRPfln2GvgFgFKXgkN5KSQXZQ7PslPBDR8VOtfPD3fx4yQ777oFT6tQkBfmZXYidG4KDeo0CxPssQ-tR3ZLdWgdxl-sD-x2cI5aNlmG37j2LbHvvp-7iBtcfmBjNsGO2CaV2N08ErGvtCbsybGrte-Co45h6xiyqe8pYj_ELXLvafMqe9HgsqPz_XmWfft0dTf5PJp-ub6ZjKejWkIBI9UIULlKxsg5AxxkQy43jS6FScYbl1cFoOCVaEoDWpGQkrQqlDSVrJTJz7Kbna4LuLDr6FfJmA3o7WMhxJnF2Pt6SVYrJWrNgZOUUqDDEpwRJMkoqoVRSevjTms9VCtyNbV9xOWR6PFL6-d2Fu6tyksutUgCb_cCMfwcqOvtIgyxTf4taA0geCnNEzXDNJVvm5DE6pXvajtWCqRRBWyHufgHlbajlU8fSI1P9aOG97uGOoaui9QcBgdutyGy2xDZfYgS_uZvswf4T2QS8G4HzH1Ky8b_pxwlhhp8oh_nk_kD-rbVPw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1881120749</pqid></control><display><type>article</type><title>Catatonia Secondary to Sudden Clozapine Withdrawal: A Case with Three Repeated Episodes and a Literature Review</title><source>Wiley Online Library Open Access</source><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Bilbily, John ; de Leon, Jose ; McCollum, Betsy</creator><contributor>Inada, Toshiya</contributor><creatorcontrib>Bilbily, John ; de Leon, Jose ; McCollum, Betsy ; Inada, Toshiya</creatorcontrib><description>A literature search identified 9 previously published cases that were considered as possible cases of catatonia secondary to sudden clozapine withdrawal. Two of these 9 cases did not provide enough information to make a diagnosis of catatonia according to the Diagnostic and Statistical Manual, 5th Edition (DSM-5). The Liverpool Adverse Drug Reaction (ADR) Causality Scale was modified to assess ADRs secondary to drug withdrawal. From the 7 published cases which met DSM-5 catatonia criteria, using the modified scale, we established that 3 were definitive and 4 were probable cases of catatonia secondary to clozapine withdrawal. A new definitive case is described with three catatonic episodes which (1) occurred after sudden discontinuation of clozapine in the context of decades of follow-up, (2) had ≥3 of 12 DSM-5 catatonic symptoms and serum creatinine kinase elevation, and (3) required medical hospitalization and intravenous fluids. Clozapine may be a gamma-aminobutyric acid (GABA) receptor agonist; sudden clozapine withdrawal may explain a sudden decrease in GABA activity that may contribute to the development of catatonic symptoms in vulnerable patients. Based on the limited information from these cases, the pharmacological treatment for catatonia secondary to sudden clozapine withdrawal can include benzodiazepines and/or restarting clozapine.</description><identifier>ISSN: 2090-682X</identifier><identifier>EISSN: 2090-6838</identifier><identifier>DOI: 10.1155/2017/2402731</identifier><identifier>PMID: 28396815</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Publishing Corporation</publisher><subject>Anesthesia ; Case Report ; Causality ; Clozapine ; Colleges &amp; universities ; GABA ; Hospitals ; Medical research ; Mental disorders ; Mental health ; Neurosciences ; Patients ; Psychosis ; Psychotropic drugs</subject><ispartof>Case reports in psychiatry, 2017-01, Vol.2017 (2017), p.1-11</ispartof><rights>Copyright © 2017 John Bilbily et al.</rights><rights>COPYRIGHT 2017 John Wiley &amp; Sons, Inc.</rights><rights>Copyright © 2017 John Bilbily et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright © 2017 John Bilbily et al. 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4161-5f21535402edd91014fed39f8729115fd3b61a20b2f79185e244e856549b4b593</citedby><cites>FETCH-LOGICAL-c4161-5f21535402edd91014fed39f8729115fd3b61a20b2f79185e244e856549b4b593</cites><orcidid>0000-0002-7756-2314</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1881120749/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1881120749?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,44590,53791,53793,74998</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28396815$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Inada, Toshiya</contributor><creatorcontrib>Bilbily, John</creatorcontrib><creatorcontrib>de Leon, Jose</creatorcontrib><creatorcontrib>McCollum, Betsy</creatorcontrib><title>Catatonia Secondary to Sudden Clozapine Withdrawal: A Case with Three Repeated Episodes and a Literature Review</title><title>Case reports in psychiatry</title><addtitle>Case Rep Psychiatry</addtitle><description>A literature search identified 9 previously published cases that were considered as possible cases of catatonia secondary to sudden clozapine withdrawal. Two of these 9 cases did not provide enough information to make a diagnosis of catatonia according to the Diagnostic and Statistical Manual, 5th Edition (DSM-5). The Liverpool Adverse Drug Reaction (ADR) Causality Scale was modified to assess ADRs secondary to drug withdrawal. From the 7 published cases which met DSM-5 catatonia criteria, using the modified scale, we established that 3 were definitive and 4 were probable cases of catatonia secondary to clozapine withdrawal. A new definitive case is described with three catatonic episodes which (1) occurred after sudden discontinuation of clozapine in the context of decades of follow-up, (2) had ≥3 of 12 DSM-5 catatonic symptoms and serum creatinine kinase elevation, and (3) required medical hospitalization and intravenous fluids. Clozapine may be a gamma-aminobutyric acid (GABA) receptor agonist; sudden clozapine withdrawal may explain a sudden decrease in GABA activity that may contribute to the development of catatonic symptoms in vulnerable patients. Based on the limited information from these cases, the pharmacological treatment for catatonia secondary to sudden clozapine withdrawal can include benzodiazepines and/or restarting clozapine.</description><subject>Anesthesia</subject><subject>Case Report</subject><subject>Causality</subject><subject>Clozapine</subject><subject>Colleges &amp; universities</subject><subject>GABA</subject><subject>Hospitals</subject><subject>Medical research</subject><subject>Mental disorders</subject><subject>Mental health</subject><subject>Neurosciences</subject><subject>Patients</subject><subject>Psychosis</subject><subject>Psychotropic drugs</subject><issn>2090-682X</issn><issn>2090-6838</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqNkkFvEzEQhVcIRKvSG2dkiSOk9XjtXZsDUhSVUikSEi2CmzW7nk0cJevg3W0Ev75OE1IiccA-2Bp_8zRPfln2GvgFgFKXgkN5KSQXZQ7PslPBDR8VOtfPD3fx4yQ777oFT6tQkBfmZXYidG4KDeo0CxPssQ-tR3ZLdWgdxl-sD-x2cI5aNlmG37j2LbHvvp-7iBtcfmBjNsGO2CaV2N08ErGvtCbsybGrte-Co45h6xiyqe8pYj_ELXLvafMqe9HgsqPz_XmWfft0dTf5PJp-ub6ZjKejWkIBI9UIULlKxsg5AxxkQy43jS6FScYbl1cFoOCVaEoDWpGQkrQqlDSVrJTJz7Kbna4LuLDr6FfJmA3o7WMhxJnF2Pt6SVYrJWrNgZOUUqDDEpwRJMkoqoVRSevjTms9VCtyNbV9xOWR6PFL6-d2Fu6tyksutUgCb_cCMfwcqOvtIgyxTf4taA0geCnNEzXDNJVvm5DE6pXvajtWCqRRBWyHufgHlbajlU8fSI1P9aOG97uGOoaui9QcBgdutyGy2xDZfYgS_uZvswf4T2QS8G4HzH1Ky8b_pxwlhhp8oh_nk_kD-rbVPw</recordid><startdate>20170101</startdate><enddate>20170101</enddate><creator>Bilbily, John</creator><creator>de Leon, Jose</creator><creator>McCollum, Betsy</creator><general>Hindawi Publishing Corporation</general><general>Hindawi</general><general>John Wiley &amp; Sons, Inc</general><general>Hindawi Limited</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>AHMDM</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-7756-2314</orcidid></search><sort><creationdate>20170101</creationdate><title>Catatonia Secondary to Sudden Clozapine Withdrawal: A Case with Three Repeated Episodes and a Literature Review</title><author>Bilbily, John ; de Leon, Jose ; McCollum, Betsy</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4161-5f21535402edd91014fed39f8729115fd3b61a20b2f79185e244e856549b4b593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Anesthesia</topic><topic>Case Report</topic><topic>Causality</topic><topic>Clozapine</topic><topic>Colleges &amp; universities</topic><topic>GABA</topic><topic>Hospitals</topic><topic>Medical research</topic><topic>Mental disorders</topic><topic>Mental health</topic><topic>Neurosciences</topic><topic>Patients</topic><topic>Psychosis</topic><topic>Psychotropic drugs</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bilbily, John</creatorcontrib><creatorcontrib>de Leon, Jose</creatorcontrib><creatorcontrib>McCollum, Betsy</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>قاعدة العلوم الإنسانية - e-Marefa Humanities</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Databases</collection><collection>ProQuest One Community College</collection><collection>Middle East &amp; Africa Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Case reports in psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bilbily, John</au><au>de Leon, Jose</au><au>McCollum, Betsy</au><au>Inada, Toshiya</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Catatonia Secondary to Sudden Clozapine Withdrawal: A Case with Three Repeated Episodes and a Literature Review</atitle><jtitle>Case reports in psychiatry</jtitle><addtitle>Case Rep Psychiatry</addtitle><date>2017-01-01</date><risdate>2017</risdate><volume>2017</volume><issue>2017</issue><spage>1</spage><epage>11</epage><pages>1-11</pages><issn>2090-682X</issn><eissn>2090-6838</eissn><abstract>A literature search identified 9 previously published cases that were considered as possible cases of catatonia secondary to sudden clozapine withdrawal. Two of these 9 cases did not provide enough information to make a diagnosis of catatonia according to the Diagnostic and Statistical Manual, 5th Edition (DSM-5). The Liverpool Adverse Drug Reaction (ADR) Causality Scale was modified to assess ADRs secondary to drug withdrawal. From the 7 published cases which met DSM-5 catatonia criteria, using the modified scale, we established that 3 were definitive and 4 were probable cases of catatonia secondary to clozapine withdrawal. A new definitive case is described with three catatonic episodes which (1) occurred after sudden discontinuation of clozapine in the context of decades of follow-up, (2) had ≥3 of 12 DSM-5 catatonic symptoms and serum creatinine kinase elevation, and (3) required medical hospitalization and intravenous fluids. Clozapine may be a gamma-aminobutyric acid (GABA) receptor agonist; sudden clozapine withdrawal may explain a sudden decrease in GABA activity that may contribute to the development of catatonic symptoms in vulnerable patients. Based on the limited information from these cases, the pharmacological treatment for catatonia secondary to sudden clozapine withdrawal can include benzodiazepines and/or restarting clozapine.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>28396815</pmid><doi>10.1155/2017/2402731</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-7756-2314</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2090-682X
ispartof Case reports in psychiatry, 2017-01, Vol.2017 (2017), p.1-11
issn 2090-682X
2090-6838
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_8552c8010e4442ada71d92e4e95ec295
source Wiley Online Library Open Access; Publicly Available Content Database; PubMed Central
subjects Anesthesia
Case Report
Causality
Clozapine
Colleges & universities
GABA
Hospitals
Medical research
Mental disorders
Mental health
Neurosciences
Patients
Psychosis
Psychotropic drugs
title Catatonia Secondary to Sudden Clozapine Withdrawal: A Case with Three Repeated Episodes and a Literature Review
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T03%3A46%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Catatonia%20Secondary%20to%20Sudden%20Clozapine%20Withdrawal:%20A%20Case%20with%20Three%20Repeated%20Episodes%20and%20a%20Literature%20Review&rft.jtitle=Case%20reports%20in%20psychiatry&rft.au=Bilbily,%20John&rft.date=2017-01-01&rft.volume=2017&rft.issue=2017&rft.spage=1&rft.epage=11&rft.pages=1-11&rft.issn=2090-682X&rft.eissn=2090-6838&rft_id=info:doi/10.1155/2017/2402731&rft_dat=%3Cgale_doaj_%3EA551495615%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4161-5f21535402edd91014fed39f8729115fd3b61a20b2f79185e244e856549b4b593%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1881120749&rft_id=info:pmid/28396815&rft_galeid=A551495615&rfr_iscdi=true